Determination of lymph nodes enriched in tumor reactive cells th

Details Determination of lymph nodes enriched in tumor reactive cells th Determination of lymph nodes enriched in tumor reactive cells th

1994-07-13

1998-09-29

Huff, Sheela

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antibody or antibody fragment or immunoglobulin;...

424 91, 424 9322, 424 931, 424 937, 424 117, 424 141, 424 153, 424 157, 436 64, 435 724, 435372, 4353722, A61K 5100, G01N 100

Patent

active

058142959

ABSTRACT:
The present invention is directed to a method for reliably determining lymph nodes enriched in tumor reactive cells, e.g., CD4+tumor-specific lymphocytes. This method includes the steps of administering to a patient an effective amount of a radiolabeled locator which specifically binds a marker produced by or associated with neoplastic tissue. Time is permitted to elapse following the administration for the radiolabeled locator to preferentially concentrate in any neoplastic tissue and for unbound radiolabeled locator to be cleared, so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in the patient. After the time has elapsed, the patient is accessed with a radiation detection probe for determining lymph node sites exhibiting accretion of the radiolabeled locator by detecting with the probe elevated levels of radiation at the lymph node sites. The lymph node sites exhibiting such elevated levels of radiation are removed and subjected to gross visual analysis, though such sites alternatively may be subjected to histological analysis. Those determined and removed lymph nodes that also are determined to be tumor-free by gross observation or free of gross metastatic disease are selected and cultured to proliferate tumor reactive cells. The selected lymph nodes are subjected to mitogenic stimulation. The lymph nodes are cultured in the presence of Interleukin-2, anti-CD.sub.3 monoclonal antibody, and neoplastic tissue which may be autologous or allogeneic tumor. The tumor reactive cells, proliferated can be used with adoptive immunotherapy regimens for mitigating the progression of tumor.

REFERENCES:
patent: 4741900 (1988-05-01), Alvarez et al.
patent: 4782840 (1988-11-01), Martin, Jr. et al.
patent: 5041289 (1991-08-01), Phillips et al.
patent: 5126132 (1992-06-01), Rosenberg
Morecki et al, Journal of Biological Response Modifiers, vol. 9 p. 463, 1990.
Yoshizawa et al, J. Immunol. vol. 147 p. 729, Jul. 1991.

Affiliated with

Also associated with

Rating

Determination of lymph nodes enriched in tumor reactive cells th does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Determination of lymph nodes enriched in tumor reactive cells th, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determination of lymph nodes enriched in tumor reactive cells th will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-683953